SequelSEC

ALUMIS INC. ALMS

Pharmaceutical Preparations · CIK 0001847367 · Fiscal year ends 1231

Revenue
$7.40M
Fiscal year ended 2026-06-30
Operating income
-$459.00M
Fiscal year ended 2026-06-30
Free cash flow
-$351.80M
Fiscal year ended 2026-06-30

ALUMIS INC. (ALMS) reported revenue of $7.40M and net income of -$438.96M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ALUMIS INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ALUMIS INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$7.40M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$459.00M
Net income-$438.96M
Research & development$347.50M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$77.08M
Selling & marketingUnavailable

Balance

ALUMIS INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$63.71M
Total assets$560.62M
Current assets$514.08M
Total liabilities$108.46M
Current liabilities$76.23M
Total equity incl. NCI$452.16M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$12.80M

Cash flow

ALUMIS INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$351.40M
Capital expenditures$401.00K
Investing cash flow-$97.94M
Financing cash flow$360.93M
Net change in cashUnavailable
Stock-based compensation$44.51M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$3.44M

Derived

ALUMIS INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$351.80M
Gross marginUnavailable
Operating margin-6204.4%
FCF margin-4755.3%
SBC / revenue601.6%
Current ratio6.74x
Revenue YoY growthUnavailable
Net margin-5933.5%
R&D / revenue4697.2%
CapEx / revenue5.4%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ALMS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-19View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.